- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04754854
Redução da Recirculação Sanguínea na ECMO Veno-Venosa
Redução da Recirculação Sanguínea em ECMO Veno-Venosa Através de Medidas de Diluição por Ultrassom (Estudo de Circulação ECMO)
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Visão geral do estudo
Status
Descrição detalhada
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
State of Berlin
-
Berlin, State of Berlin, Alemanha, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Inclusion Criteria:
- patients aged 18 years or older
- ARDS
- veno-venous ECMO
Exclusion Criteria:
- age < 18 years
- hemodynamic instability during measurement of recirculation
- pregnancy
- inability to obtain patient's consent or consent of legal guardian
Descrição
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Successful ECMO blood flow reduction
Prazo: Once within the first week after initiation of ECMO therapy
|
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction |
Once within the first week after initiation of ECMO therapy
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recirculation fraction
Prazo: Once within the first week after initiation of ECMO therapy
|
Fraction of blood recirculating through the ECMO circuit |
Once within the first week after initiation of ECMO therapy
|
|
Arterial blood oxygen content
Prazo: Once within the first week after initiation of ECMO therapy
|
Arterial blood oxygen content before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal blood Flow
Prazo: Once within the first week after initiation of ECMO therapy
|
ECMO Blood Flow before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal gas flow
Prazo: Once within the first week after initiation of ECMO therapy
|
ECMO Sweep Gas flow |
Once within the first week after initiation of ECMO therapy
|
|
Length of ECMO therapy
Prazo: Daily until the end of ECMO therapy (approximately 14 days)
|
Days on ECMO |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Cannula position and distance
Prazo: Once within the first week after initiation of ECMO therapy
|
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans) |
Once within the first week after initiation of ECMO therapy
|
|
Right heart dysfunction
Prazo: Once within the first week after initiation of ECMO therapy
|
Existing echocardiography will be evaluated for possible right heart dysfunction |
Once within the first week after initiation of ECMO therapy
|
|
Length of mechanical ventilation
Prazo: Entire duration of the ICU stay (approximately 28 days)
|
Length of mechanical ventilation |
Entire duration of the ICU stay (approximately 28 days)
|
|
Complications of ECMO therapy
Prazo: Length of ECMO therapy (approximately 14 days)
|
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis |
Length of ECMO therapy (approximately 14 days)
|
|
ICU mortality
Prazo: Entire duration of the ICU stay (approximately 28 days)
|
ICU mortality |
Entire duration of the ICU stay (approximately 28 days)
|
|
ICU length of stay
Prazo: Entire duration of the ICU stay (approximately 28 days)
|
ICU length of stay |
Entire duration of the ICU stay (approximately 28 days)
|
|
Incidence of ICU-acquired organ dysfunctions and complications
Prazo: Entire duration of the ICU stay (approximately 28 days)
|
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections |
Entire duration of the ICU stay (approximately 28 days)
|
|
ECMO blood flow over time
Prazo: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO blood and sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
ECMO sweep gas flow over time
Prazo: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Mobility at ICU discharge
Prazo: Discharge from the ICU (approximately 28 days)
|
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently) |
Discharge from the ICU (approximately 28 days)
|
|
Weaning level at ICU discharge
Prazo: Discharge from the ICU (approximately 28 days)
|
Level of weaning reached at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Status of mechanical ventilation at ICU discharge
Prazo: Discharge from the ICU (approximately 28 days)
|
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters |
Discharge from the ICU (approximately 28 days)
|
|
Level of organ dysfunction at ICU discharge
Prazo: Discharge from the ICU (approximately 28 days)
|
Sepsis-related Organ Failure Assessment Score at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of consciousness at ICU discharge
Prazo: Discharge from the ICU (approximately 28 days)
|
Glasgow Coma Scale at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of disease severity
Prazo: Discharge from the ICU (approximately 28 days)
|
Acute Physiology And Chronic Health Evaluation at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Hospital acquired infections related to ECMO therapy
Prazo: Entire duration of ECMO therapy
|
Infection/colonisation of the ECMO circuit |
Entire duration of ECMO therapy
|
|
Bleeding and thrombembolic complications of ECMO therapy
Prazo: Entire duration of ECMO therapy
|
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit |
Entire duration of ECMO therapy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Martin Russ, Dr. med., Charite University Hospital Berlin
- Investigador principal: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
- Investigador principal: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
- Investigador principal: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- EA115620
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .